More on the WAG-BIOS deal (previous): BioScrip (BIOS) will come out of the deal considerably...

|By:, SA News Editor

More on the WAG-BIOS deal (previous): BioScrip (BIOS) will come out of the deal considerably leaner, but will still have its infusion, home health, pharmacy benefit management and cash card businesses. The firm also say that it will continue to service its infusion patient base and managed care customers through its pharmacies. Shares of BIOS are currently halted.